Pfizer Inc (PFE)
Quick ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 2,853,000 | 3,148,000 | 2,632,000 | 2,166,000 | 416,000 | 1,298,000 | 1,780,000 | 2,470,000 | 1,944,000 | 1,966,000 | 2,372,000 | 1,768,000 | 1,786,000 | 1,587,000 | 1,801,000 | 2,151,000 | 1,121,000 | 2,785,000 | 1,784,000 | 1,937,000 |
| Short-term investments | US$ in thousands | 19,674,000 | 82,066,000 | 84,306,000 | 17,806,000 | 44,632,000 | 34,825,000 | 31,524,000 | 21,427,000 | 58,250,000 | 27,730,000 | 19,328,000 | 11,899,000 | 10,437,000 | 20,325,000 | 20,993,000 | 8,199,000 | 8,525,000 | 6,302,000 | 11,128,000 | 9,682,000 |
| Receivables | US$ in thousands | 11,177,000 | 11,086,000 | 10,231,000 | — | 10,952,000 | — | — | — | 11,479,000 | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 47,794,000 | 31,136,000 | 34,647,000 | 36,562,000 | 42,138,000 | 44,314,000 | 47,410,000 | 39,268,000 | 42,671,000 | 41,803,000 | 35,664,000 | 26,652,000 | 25,920,000 | 34,154,000 | 32,723,000 | 33,890,000 | 37,304,000 | 36,974,000 | 32,030,000 | 29,423,000 |
| Quick ratio | 0.71 | 3.09 | 2.80 | 0.55 | 1.33 | 0.82 | 0.70 | 0.61 | 1.68 | 0.71 | 0.61 | 0.51 | 0.47 | 0.64 | 0.70 | 0.31 | 0.26 | 0.25 | 0.40 | 0.39 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($2,853,000K
+ $19,674,000K
+ $11,177,000K)
÷ $47,794,000K
= 0.71
The quick ratio of Pfizer Inc. has varied over the past eight quarters, reflecting fluctuations in the company's liquidity position. In Q4 2023, the quick ratio was at 0.69, indicating a decrease in liquidity compared to the previous quarter. This may raise concerns about Pfizer's ability to meet its short-term obligations with its most liquid assets.
In Q3 2023, the quick ratio surged to 2.05, suggesting a significant improvement in liquidity compared to the previous quarter. This increase may signal that Pfizer had more than enough liquid assets to cover its short-term liabilities.
The quick ratio remained relatively stable in Q2 2023 at 1.82, indicating a healthy liquidity position. However, in Q1 2023, the quick ratio dropped to 1.11, showing a decrease in liquidity compared to the previous quarter.
Comparing Q4 2023 to the quick ratio in the same quarter of the previous year (Q4 2022) at 1.00, there seems to be an improvement in liquidity over this one-year period. However, the quick ratio has been somewhat volatile during the quarters in between.
Overall, it is essential for Pfizer to closely monitor its quick ratio to ensure that it maintains a healthy balance between its liquid assets and short-term liabilities to support its ongoing operations and financial stability.
Peer comparison
Dec 31, 2023